Optimizing outcomes in multiple sclerosis - A consensus initiative

Multiple Sclerosis

Volumn 15, Issue SUPPL. 2, 2009, Pages

  Coyle, P ^a   Arnason, B ^a   Hurwitz, B ^a   Lublin, F ^a  

^a STONY BROOK UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Clinically isolated syndrome; Copolymer 1; Interferon beta 1a; Interferon beta 1b; McDonald Criteria; Mitoxantrone; Multiple sclerosis; Natalizumab

Indexed keywords

ALEMTUZUMAB; AZATHIOPRINE; BETA INTERFERON; BETA1A INTERFERON; CLADRIBINE; CORTICOSTEROID; CORTISONE; CYCLOPHOSPHAMIDE; DACLIZUMAB; GLATIRAMER; GLUCOCORTICOID; IMMUNOGLOBULIN; INTERFERON BETA SERINE; LAQUINIMOD; METHOTREXATE; METHYLPREDNISOLONE; MITOXANTRONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NATALIZUMAB; NEUTRALIZING ANTIBODY; PLACEBO; RITUXIMAB; TEMSIROLIMUS;

ACUTE GRAFT REJECTION; ANTIBODY PRODUCTION; ARTICLE; AUTOIMMUNE DISEASE; BONE MARROW SUPPRESSION; CARDIOTOXICITY; CLINICAL DECISION MAKING; CLINICAL TRIAL; CONSENSUS DEVELOPMENT; DEMYELINATION; DOSAGE SCHEDULE COMPARISON; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG ERUPTION; DRUG MEGADOSE; DRUG SAFETY; DRUG TREATMENT FAILURE; EARLY INTERVENTION; FLU LIKE SYNDROME; GASTROINTESTINAL SYMPTOM; HAIRY CELL LEUKEMIA; HUMAN; HYPERLIPIDEMIA; IMMUNOMODULATION; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; INJECTION SITE REACTION; INSOMNIA; LIVER TOXICITY; LOW DRUG DOSE; MALIGNANT NEOPLASTIC DISEASE; MENSTRUATION DISORDER; MENTAL DISEASE; MORNING DOSAGE; MOUTH INFLAMMATION; MOUTH ULCER; MULTIPLE SCLEROSIS; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; PATIENT MONITORING; PROGNOSIS; RECURRENCE RISK; RISK ASSESSMENT; SKIN DISEASE; SURVIVAL RATE; THROMBOCYTOPENIC PURPURA; THYROID DISEASE; UNSPECIFIED SIDE EFFECT;

EID: 65249171522     PISSN: 13524585     EISSN: None     Source Type: Journal    
DOI: 10.1177/1352458508101134     Document Type: Article

References (101)

1. National MS Society. Available at: http://www.nationalmssociety.org. Accessed July 9, 2008.
2. PRISMS Study Group. Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group. Lancet 1998; 359: 1498 - 1504.
3. Jacobs LD Beck RW Simon JH Kinkel RP Brownscheidle CM Murray TJ. Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group. N Engl J Med 2000; 343: 898 - 904.
4. Comi G Filippi M Barkhof F Durelli L Edan G Fernandez O. Effect of early interferon treatment on conversion to definite multiple sclerosis: A randomized study. Lancet 2001; 357: 1576 - 1582.
5. Kappos L Polman CH Freedman MS Edan G Hartung HP Miller DH. Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes. Neurology 2006; 67: 1242 - 1249.
6. Kappos L Freedman MS Polman CH Edan G Hartung HP Miller DH. Effect of early versus delayed interferon beta-1b treatment on disability after a first clinical event suggestive of multiple sclerosis: A 3-year follow-up analysis of the BENEFIT study. Lancet 2007; 370: 389 - 397.
7. Goodin DS Frohman EM Garmany GP Halper J Likosky WH Lublin FD. Disease modifying therapies in multiple sclerosis: Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines. Neurology 2002; 58: 169 - 178.
8. Frohman EM Goodin DS Calabresi PA Corboy JR Coyle PK Filippi M. The utility of MRI in suspected MS: Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 2003; 61: 602 - 611.
9. Miller D Barkhof F Montalban X Thompson A Filippi M. Clinically isolated syndromes suggestive of multiple sclerosis, part I: Natural history, pathogenesis, diagnosis, and prognosis. Lancet Neurol 2005; 4: 281 - 288.
10. Brex PA Ciccarelli O O'Riordan JI Sailer M Thompson J Miller DH. A longitudinal study of abnormalities on MRI and disability from multiple sclerosis. N Engl J Med 2002; 346: 158 - 164.
11. O'Riordan JI Thompson AJ Kingsley DP MacManus DG Kendall BE Rudge P. The prognostic value of brain MRI in clinically isolated syndromes of the CNS. A 10-year follow-up. Brain 1998; 121: 495 - 503.
12. Lovrecić L Ristić S Starcević-Cizmarevć N Jazbec SS Sepcić J Kapović M. Angiotensin-converting enzyme I/D gene polymorphism and risk of multiple sclerosis. Acta Neurol Scand 2006; 114: 374 - 377.
13. Avasarala JR Cross AH Trotter JL. Oligoclonal band number as a marker for prognosis in multiple sclerosis. Arch Neurol 2001; 58: 2044 - 2045.
14. Kang, PS, Munter, FM. Optic neuritis. http://www.emedicine.com/radio/ topic488htm. Accessed June 30, 2008.
15. Lee AG Lin DJ Kaufman M Golnik KC Vaphiades MS Eggenberger E. Atypical features prompting neuroimaging in acute optic neuropathy in adults. Can J Ohthalmol 2000; 35: 325 - 330.
16. Graber DJ Levy M Kerr D Wade WF. Neuromyelitis optica pathogenesis and aquaporin 4. J Neuroinflammation 2008; 5: 22.
17. WebCare.MD. Devic's Syndrome Information Page. http://www.webcare.md/ ArticleDisplay720c2216.aspx Accessed June 30, 2008.
18. Matiello M Jacob A Wingerchuk DM Weinshenker BG. Neuromyelitis optica. Curr Opin Neurol 2007; 20: 255 - 260.
19. Lennon VA Kryzer TJ Pittock SJ Verkman AS Hinson SR. IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel. J Exp Med 2005; 202: 473 - 477.
20. Wingerchuk DM Lucchinetti CF. Comparative immunopathogenesis of acute disseminated encephalomyelitis, neuromyelitis optica, and multiple sclerosis. Curr Opin Neurol 2007; 20: 343 - 350.
21. Traboulsee AL. Li DK. The role of MRI in the diagnosis of multiple sclerosis. Adv Neurol 2006; 98: 125 - 146.
22. Rocca MA Agosta F Sormani MP Fernando K Tintoré M Korteweg T. A three-year, multi-parametric MRI study in patients at presentation with CIS. J Neurol. 2008; 255: 683 - 691.
23. Zwibel, HL, Kross, JF. Data presented at ECTRIMS 2007 to assist in effective diagnosis and management of patients with MS. Available at: http://www.medscape. com/viewarticle/566550 Accessed April 23, 2008.
24. Rovira A Swanton J Tintoré M Huerga E Barkhof F Filippi M. How early can the diagnosis of multiple sclerosis be ascertained with a single MRI scan? Programs and abstracts of the ECTRIMS 2007: 23rd Congress of the European Committee for Treatment and Research in Multiple Sclerosis; October 11-14, 2007; Prague, Czech Republic. Poster 270.
25. Swanton JK Rovira A Tintoré M Altmann D Barkhof F Filippi M. MRI criteria for multiple sclerosis in patients presenting with clinically isolated syndromes: A multicentre retrospective study. Lancet Neurol 2007; 6: 677 - 686.
26. McDonald W Compston A Edan G Goodkin D Hartung HP Lublin FD. Recommended diagnostic criteria for multiple sclerosis: Guidelines from the International Panel on the Diagnosis of Multiple Sclerosis. Ann Neurol 2001; 50: 121 - 127.
27. Polman CH Reingold SC Edan G Filippi M Hartung HP Kappos L Diagnostic criteria for multiple sclerosis: 2005 revisions to the "McDonald Criteria". Ann Neurol 2005; 58: 840 - 846.
28. Swanton JK Fernando K Dalton CM Miszkiel KA Thompson AJ Plant GT. Modification of MRI criteria for multiple sclerosis in patients with clinically isolated syndromes. J Neurol Neurosurg Psychiatry 2006; 77: 830 - 833.
29. Swanton JK Fernando KT Dalton CM Miszkiel KA Plant GT Thompson AJ. Brain lesion number and spinal cord lesions in clinically isolated syndrome patients and the risk for clinically definite multiple sclerosis. Programs and abstracts of the ECTRIMS 2007: 23rd Congress of the European Committee for Treatment and Research in Multiple Sclerosis; October 11-14, 2007; Prague, Czech Republic. Poster 269.
30. Tintoré M Rovira A Río J Nos C Grive E Sastre-Garriga J. New diagnostic criteria for multiple sclerosis: Application in first demyelinating episode. Neurology 2003; 60: 27 - 30.
31. Freedman MS Polman C Kappos L Edan G Hartung H-P Miller D. Betaseron in Newly Emerging Multiple Sclerosis for Initial Treatment (BENEFIT): Effects of Immediate vs. Early Onset of Interferon Beta-1b Treatment. Programs and abstracts of the American Academy of Neurology 59th Annual Meeting; April 28-May 5, 2007.; Boston, MA. Abstract S02.004.
32. Jeffrey, S. BEYOND and PRECISE results suggest equivalence for multiple sclerosis treatments. Medical News. Medscape. Available at: http://www.medscape.com/viewarticle/573185_print. Accessed April 23, 2008.
33. Kinkel RP Kollman C O'Connor P Murray TJ Simon J Arnold D. IM interferon beta-1a delays definite multiple sclerosis 5 years after a first demyelinating event. Neurology 2006; 66: 678 - 684.
34. PharmaLive. Five-year data confirm that early treatment with Betaseron at first sign of disease can delay progression to MS. September 22, 2008. Available at: http://google-sina.com/2008/09/22/ pharmalive-fiveyear-data-confirm-that-early-treatment-with-betaseronat- first-sign-of-disease-can-delay-progression-to-ms/ Accessed September 24, 2008
35. Trojano M Amao MP Avolio C Bergamaschi R Cavalla P Durelli L. The real life impact of early versus delayed treatment of interferon beta on long-term disability progression in relapsing-remitting multiple sclerosis. Presented at the 60th annual meeting of the American Academy of Neurology. Held in Chicago IL, April 13-20, 2008. Poster session.
36. Clerico M Faggiano F Palace J Rice G Intore M Durelli L. Recombinant interferon beta or glatiramer acetate for delaying conversion of the first demyelinating event to multiple sclerosis. Cochrane Database Syst Rev 2008;Apr 16;(2):CD005278.
37. Bjartmar C Trapp BD. Axonal and neuronal degeneration in multiple sclerosis: Mechanisms and functional consequences. Curr Opin Neurol 2001; 14: 271 - 278.
38. Kuhlmann T Lingfeld G Bitsch A Schuchardt J Brück W. Acute axonal damage in multiple sclerosis is most extensive in early disease stages and decreases over time. Brain 2002; 125: 2202 - 2212.
39. DeStefano N Guidi L Stromillo ML Bartolozzi ML Federico A. Imaging neuronal and axonal degeneration in multiple sclerosis. Neurol Sci 2003; 24 (suppl 5): S283 - S286.
40. Pittock SJ Lucchinetti CF. The pathology of MS: New insights and potential clinical applications. Neurologist 2007; 13: 45 - 56.
41. Glaser GH Merritt HH. Effects of ACTH and cortisone in multiple sclerosis. Trans Am Neurol Assoc 1951; 56: 130 - 133.
42. MacLean HJ Freedman MS. Immunologic therapy for relapsing-remitting multiple sclerosis. Curr Neurol Neurosci Rep 2001; 1: 277 - 285.
43. Inglese M. Multiple sclerosis: New insights and trends. AJNR Am J Neuroradiol 2006; 27: 954 - 957.
44. Comi G Pulizzi A Rovaris M Abramsky O Arbizu T Boiko A. Effect of laquinimod on MRI-monitored disease activity in patients with relapsing-remitting multiple sclerosis: A multicentre, randomised, double-blind, placebo-controlled phase IIb study. Lancet 2008; 371: 2085 - 2092.
45. Cohen JA Rovaris M Goodman AD Ladkani D Wynn D Filippi M. 9006 Study Group. Randomized, double-blind, dose comparison study of glatiramer acetate in relapsing-remitting MS. Neurology 2007; 68: 939 - 944.
46. Ruggieri RA Aviolio C Livrea P Trojano M. Glatiramer acetate in multiple sclerosis: A review. CNS Drug Rev 2007; 13: 178 - 191.
47. Chwastiak LA Ehde DM. Psychiatric issues in multiple sclerosis. Psychiatr Clin North Am 2007; 30: 803 - 817.
48. Río J Porcel J Téllez N Sánchez-Betancourt A Tintoré M Arévalo MJ. Factors related with treatment adherence to interferon beta and glatiramer acetate therapy in multiple sclerosis. Mult Scler 2005; 11: 306 - 309.
49. Daugherty KK Butler JS Mattingly M Ryan M. Factors leading patients to discontinue multiple sclerosis therapies. J Am Pharm Assoc 2005; 45: 371 - 375.
50. Devonshire V Lapierre Y MacDonell R Ramo Tello C Patti F Fontoura P. A multivariate analysis of the Global Adherence Project to determine key factors associated with adherence to multiple sclerosis disease-modifying therapies. Programs and abstracts of the ECTRIMS 2007; 23rd Congress of the European Committee for Treatment and Research in Multiple Sclerosis; October 11-14, 2007; Prague, Czech Republic. Poster 169.
51. deSeze J Borgel F Brudon F. Immunomodulator treatments and multiple sclerosis: Compliance and factors of adherence to treatment. Programs and abstracts of the ECTRIMS 2007; 23rd Congress of the European Committee for Treatment and Research in Multiple Sclerosis; October 11-14, 2007; Prague, Czech Republic. Poster 171.
52. Edan G Freedman MS Hartung H-P Kappos L Miller DH Montalbán X. Adherence, tolerability and quality of life: Betaferon® therapy over 3 years in patients with a first event suggestive of multiple sclerosis. Programs and abstracts of the ECTRIMS 2007; 23rd Congress of the European Committee for Treatment and Research in Multiple Sclerosis; October 11-14, 2007; Prague, Czech Republic. Poster 183.
53. Schwid SR Panitch HS. Full results of the Evidence of Interferon Dose-Response-European North American Comparative Efficacy (EVIDENCE) study: A multicenter, randomized, assessor-blinded comparison of low-dose weekly versus high-dose, high-frequency interferon beta-1a for relapsing multiple sclerosis. Clin Ther 2007; 29: 2031 - 2048.
54. Durelli L Verdun E Barbero P Bergui M Versino E Ghezzi A. Every-other-day interferon beta-1b versus once-weekly interferon beta-1a for multiple sclerosis: Results of a 2-year prospective randomised multicentre study (INCOMIN). Lancet 2002; 359: 1453 - 1460.
55. Coyle PK Barkhof F Chang P Jeffery DR Mikol DD Stubinski B. The REGARD trial: Safety and immunogenicity from a randomised, assessor-blinded trial of interferon beta-1a and glatiramer acetate in relapsing-remitting multiple sclerosis. Programs and abstracts of the ECTRIMS 2007; 23rd Congress of the European Committee for Treatment and Research in Multiple Sclerosis; October 11-14, 2007; Prague, Czech Republic. Poster 232B.
56. Mikol DD Barkhof F Chang P Coyle PK Jeffery DR Schwid SR. Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): A multicentre, randomized, parallel, open-label trial. Lancet Neurol. 2008; (Sep): 10 [Epub ahead of print].
57. Teva Provides Update on FORTE Trial. Monday, July 7, 2008. http://www.reuters.com/article/pressRelease/ idUS48312+07-Jul-2008+BW20080707. Accessed August 28, 2008.
58. Durelli L. Dose and frequency of interferon treatment matter - INCOMIN and OPTIMS. J Neurol 2003; 250 (Suppl 4): IV9 - IV14.
59. Judica E Rovaris M Ceccarelli A Ghezzi A Martinelli V Comi G. A three-year diffusion tensor MRI study of grey matter damage progression during the earliest clinical stages of multiple sclerosis. Programs and abstracts of the ECTRIMS 2007; 23rd Congress of the European Committee for Treatment and Research in Multiple Sclerosis; October 11-14, 2007; Prague, Czech Republic. Poster 635.
60. Chiu A Richert N Ehrmantraut M Ohayon J Cantor F Frank J. Characterisation of response to treatment with interferon beta-1b using contrast-enhancing lesions lesion frequency as a primary outcome measure: A 3-year monthly imaging study. Programs and abstracts of the ECTRIMS 2007; 23rd Congress of the European Committee for Treatment and Research in Multiple Sclerosis; October 11-14, 2007; Prague, Czech Republic. Poster 637.
61. The IFNB Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. The IFNB Multiple Sclerosis Study Group. Neurology 1993; 43: 655 - 661.
62. Rudick RA Goodkin DE Jacobs LD Cookfair DL Herndon RM Richert JR. Impact of interferon beta-1a on neurologic disability in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG). Neurology 1997; 49: 358 - 363.
63. Durelli L Barbero P Bergui M Versino E Bassano MA Verdun E. MRI activity and neutralizing antibody as predictors of response to interferon beta treatment in multiple sclerosis. J Neurol Neurosurg Psychiatry 2008; 79: 646 - 651.
64. Kappos L. Effects of drugs in secondary disease progression in patients with multiple sclerosis Mult Scler 2004; 10(suppl. 1): S46 - S54.
65. Fox EJ. Management of worsening multiple sclerosis with mitoxantrone: A review. Clin Ther 2006; 28: 461 - 474.
66. Cocco E Marchi P Sardu C Russo P Paolillo A Mascia M. Mitoxantrone treatment in patients with early relapsing-remitting multiple sclerosis. Mult Scler 2007; 13: 975 - 980.
67. LePage E Leray E Taurin G Coustans M Chaperon J Morrisey SP. Mitoxantrone as induction treatment in aggressive relapsing remitting multiple sclerosis: Treatment response factors in a 5 year follow-up observational study of 100 consecutive patients. J Neurol Neurosurg Psychiatry 2008; 79: 52 - 56.
68. Zipoli V Portaccio E Hakiki B Siracusa G Sorbi S Amato MP. Intravenous mitoxantrone and cyclophophamide as second-line therapy in multiple sclerosis: An open-label comparative study of efficacy and safety. J Neurol Sci 2008; 266: 25 - 30.
69. Rovaris M Confavreux C Furlan R Kappos L Comi G Filippi M. Secondary progressive multiple sclerosis: Current knowledge and future challenges. Lancet Neurol. 2006; 5: 343 - 354.
70. Brown MG Kirby S Skedgel C Fisk JD Murray TJ Bhan V. How effective are disease-modifying drugs in delaying the progression in relapsing-onset MS. Neurology 2007; 69: 1498 - 1507.
71. Cadavid D Wolansky L Cook S Halper J Hill J Younes M. Betaseron versus copaxone in multiple sclerosis with triple-dose gadolinium and 3 Tesla MRI Endpoints (BECOME): Announcement of secondary clinical outcomes. Programs and abstracts of the ECTRIMS 2007; 23rd Congress of the European Committee for Treatment and Research in Multiple Sclerosis; October 11-14, 2007; Prague, Czech Republic. Poster 207.
72. Polman CH O'Connor PW Havrdova E Hutchinson M Kappos L Miller DH. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 2006; 354: 899 - 910.
73. Patti F Amato MP Caniatti L Di Monte E Ferrazza P Goretti B. Effects of two different doses of subcutaneous interferon beta-1a treatment on cognition in patients with early relapsing-remitting multiple sclerosis. Programs and abstracts of the ECTRIMS 2007: 23rd Congress of the European Committee for Treatment and Research in Multiple Sclerosis; October 11-14, 2007; Prague, Czech Republic. Poster 200.
74. King, M. A new view of progressive MS-multiple sclerosis. Inside MS. Summer 2000. http://findarticles.com/p/articles/mi_m0850/is_3_18/ ai_63690615/print Accessed January 19, 2008.
75. Mostert JP de Groot JC Ramsaransing GS Koch MW De Keyser J. Relationship between the extent of T2 lesions and the onset of secondary progression in multiple sclerosis. Eur J Neurol 2007; 14: 1210 - 1215.
76. Río J Tintoré M Nos C Téllez N Galán I Pelayo R. Interferon beta in secondary progressive multiple sclerosis: Daily clinical practice. J Neurol 2007; 254: 849 - 853.
77. Ramo C Grau L. Clinical predictors of spontaneous benign multiple sclerosis. Programs and abstracts of the ECTRIMS 2007: 23rd Congress of the European Committee for Treatment and Research in Multiple Sclerosis; October 11-14, 2007; Prague, Czech Republic. Poster 701.
78. Frederiksen J Nygaard M. Predictors of a benign course in multiple sclerosis. Programs and abstracts of the ECTRIMS 2007; 23rd Congress of the European Committee for Treatment and Research in Multiple Sclerosis; October 11-14, 2007; Prague, Czech Republic. Poster 702.
79. Wu X Kuusisto H Dastidar P Huhtala H Nikkari ST Ukkonen M. Once-weekly 22microg subcutaneous IFN-beta-1a in secondary progressive MS: A 3-year follow-up study on brain MRI measurements and serum MMP-9 levels. Acta Neurol Scand. 2007; 116: 43 - 48.
80. Scott LJ Figgitt DP. Mitoxantrone: A review of its use in multiple sclerosis. CNS Drugs. 2004; 18: 379 - 396.
81. Buttinelli C Clemenzi A Borriello G Denaro F Pozzilli C Fieschi C. Mitoxantrone treatment in multiple sclerosis: A 5-year clinical and MRI follow-up. Eur J Neurol 2007; 14: 1281 - 1287.
82. Hartung H Gonsett R Konig N Kwiecinski H Guseo A Morrissey H. Mitoxantrone in progressive multiple sclerosis: A placebo-controlled, double-blind, randomized, multicentre trial. Lancet 2002; 360: 2018 - 2025.
83. Durelli L Ferrero B Ghezzi A Montanari E Zaffaroni M Bergui M. The Independent Comparison of Interferon (INCOMIN) Trial: A multicentre randomised trial comparing clinical and MRI efficacy of IFN beta-1a and beta-1b in multiple sclerosis. Annual meeting of the American Academy of Neurology; Philadelphia; April 2001. Neurology April 2001; 56 (Suppl. 3).
84. Jeffery DR. Use of combination therapy with immunomodulators and immunosuppressants in treating multiple sclerosis. Neurology 2004; 63 (suppl 6): S41 - S46.
85. Rudick RA Stuart WH Calabresi PA Confavreux C Galetta SL Radue EW. Natalizumab plus interferon beta-1a for relapsing multiple sclerosis. N Engl J Med 2006; 354: 911 - 923.
86. Casetta I Iuliano G Filippini G. Azathioprine for multiple sclerosis. Cochrane Database Syst Rev 2007; (4): CD003982.
87. Krishnan C Kaplin AI Brodsky RA Drachman DB Jones RJ Pham DL. Reduction of disease activity and disability with high-dose cyclophosphamide in patients with aggressive multiple sclerosis. Arch Neurol 2008; 65: 1044 - 1051.
88. Gladstone DE Zamkoff KW Krupp L Peyster R Sibony P Christodoulou C. High-dose cyclophosphamide for moderate to severe refractory multiple sclerosis. Arch Neurol 2006; 63: 1388 - 1393.
89. Fazekas F Lublin FD Li D Freedman MS Hartung HP Rieckmann P. Intravenous immunoglobulin in relapsing-remitting multiple sclerosis: A dose-finding trial. Neurology 2008; 71: 265 - 271.
90. UCSF Multiple Sclerosis Center. Treatments for MS. http://neurology.ucsf.edu/msc/treatments.htm. Accessed September 4, 2008.
91. Davies SL Moral MA. Spotlight on: Clinical development of mycophenolate mofetil in multiple sclerosis. Drug News Perspect 2006; 19: 623 - 633.
92. Pawate S Wang L Sriram S Moses H. Mycophenolate mofetil in the treatment of multiple sclerosis. Presented at the 60th annual meeting of the American Academy of Neurology. Held in Chicago IL, April 13-20, 2008.
93. Multiple Sclerosis Newsletter. Research updates. August September 2005. Available at: http://www/fortnet.org/NCMSN/0805.html Accessed July 9, 2008.
94. Coles A. CAMMS 223 Study Group. Alemtuzumab compared with subcutaneous high-dose IFNB-1a in treatment-naive relapsing-remitting multiple sclerosis: Primary efficacy outcomes of CAMMS223 at 3 years. Presented at the 60th annual meeting of the American Academy of Neurology. Held in Chicago, IL April 13-20, 2008. Scientific session.
95. PDL BioPharma. Pipeline. Daclizumab. Available at: http://www.pdl.com/ index.cfm?navId=49 Accessed April 9, 2008.
96. Montalban X Wynn D Kaufman M Wang M Fong A. Preliminary CHOICE results: a phase 2, randomised, double-blind, placebo-controlled multicentre study of subcutaneous daclizumab in patients with active, relapsing forms of multiple sclerosis on interferon beta. Programs and abstracts of the ECTRIMS 2007: 23rd Congress of the European Committee for Treatment and Research in Multiple Sclerosis; October 11-14, 2007; Prague, Czech Republic. Abstract 50.
97. Goodman, A. Daclizumab plus interferon found safe and effective combination therapy for active MS. News from the AAN Annual Meeting. 2008;May 2. Available at: http://www.neurotodayonline.com/pt/re/ neurotoday/fulltext.00132985-200805020-00009.html. Accessed July 9, 2008.
98. Hauser SL Waubant E Arnold DL Vollmer T Antel J Fox RJ. B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. N Engl J Med 2008; 358: 676 - 688.
99. Clinical Trials. Gov. Clinical Trial Comparing Treatment of Relapsing-Remitting Multiple Sclerosis (RR-MS) With Two Doses of Glatriamer Acetate (GA). Available at: http://clinicaltrials.gov/ct2/ show/NCT00337779?intr=%22Copolymer+1%22&rank=13 Accessed July 14, 2008.
100. Medical News Today. Phase III trial of oral cladribine, a novel investigational therapy for multiple sclerosis begins in the United States. May 5, 2006. Available at: http://www.medicalnewstoday.com/ printerfriendlynews.php?newsid=42811 Accessed July 14, 2008.
101. Goodin DS Frohman EM Hurwitz B O'Connor PW Oger JJ Reder AT. Neutralizing antibodies to interferon beta: Assessment of their clinical and radiographic impact: An evidence report. Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 2007; 68: 977 - 984.